Baird Maintains Bullish View on Intercept Pharmaceuticals (ICPT), Concerns Overblown

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Baird Maintains Bullish View on Intercept Pharmaceuticals (ICPT), Concerns Overblown

Intercept Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update

November 3, 2016 7:05 AM EDT

Net Ocaliva® (obeticholic acid or OCA) 3Q sales of $4.7 million Positive opinion adopted by Committee of Medicinal Products in Human Use (CHMP) for Ocaliva in Primary Biliary Cholangitis (PBC) in EUEnrollment in Phase 2 CONTROL trial complete in Nonalcoholic Steatohepatitis (NASH) patients with fibrosisEnrollment in Phase 2 AESOP trial complete in primary sclerosing cholangitis (PSC)

Conference call scheduled for 8:30 a.m. ET today

NEW YORK, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.... More